



NEWS RELEASE

# ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series

8/7/2023

Presentations and live Q&A to take place on Monday, August 14 and Wednesday, August 16

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT) and Wednesday, August 16, 2023 at 2:00 p.m. ET (11:00 a.m. PT). ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.

The presentations will feature Rob Fried, Chief Executive Officer, and Brianna Gerber, Chief Financial Officer. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in either of these events will need to register using the links below. As a reminder, registration for the live events may be limited but access to the replay after the events will be on the company's Investor website. Investors may submit questions during the presentations or may email questions to [InvestorRelations@ChromaDex.com](mailto:InvestorRelations@ChromaDex.com) or [jkautz@renmarkfinancial.com](mailto:jkautz@renmarkfinancial.com) ahead of the event.

REGISTER HERE:

Monday, August 14, 2023: <https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-14-120000>

Wednesday, August 16, 2023: <https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-16-140000>

- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

## About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. ChromaDex maintains a website at [www.chromadex.com](http://www.chromadex.com) to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

## ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

[kendall.knysch@chromadex.com](mailto:kendall.knysch@chromadex.com)

## ChromaDex Investor Relations Contact:

+1 (949) 356-1620

[InvestorRelations@ChromaDex.com](mailto:InvestorRelations@ChromaDex.com)

## Renmark Financial Communications Inc.

James R. Kautz: [jkautz@renmarkfinancial.com](mailto:jkautz@renmarkfinancial.com)

Tel.: (416) 644-2020 or (212) 812-7680

[www.renmarkfinancial.com](http://www.renmarkfinancial.com)

Source: ChromaDex Corporation